



Synthesis, Reactions, and Antimicrobial Activity of *N*-Hydroxy-triacetonamine Derivatives



Mahmoud N. M. Yousif^{1*}, Ahmed A. Fayed^{1,2} and Nabil M. Yousif¹

¹Photochemistry Department, National Research Centre, Cairo, Egypt.

²Respiratory Therapy Department, Faculty of Medical Rehabilitation Sciences, Taibah University, Madinah Munawara, 22624, Saudi Arabia.

SIMPLE and one step method for preparation of *N*-hydroxy-2,2,6,6-tetramethyl-4-piperidone is reported. *N*-Hydroxy-2,2,6,6-tetramethyl-4-piperidone (**1**) reacts with formaldehyde, formaldehyde and piperidine to afford compounds (**3**) and (**4**) respectively. Compound (**1**) reacts with sodium azide and α -bromosugar to afford corresponding products. Compound (**1**) reacts with 2-(4-chlorobenzylidene)malononitrile to afford 1,6-naphthyridine derivative (**9**). *N*-Hydroxy-2,2,6,6-tetramethyl-4-piperidone (**1**) reacts with *p*-chlorobenzaldehyde and cyanoacetamide to produce 1,6-naphthyridine derivative (**10a**). *N*-Hydroxy derivative (**1**) reacts also with *p*-chlorobenzaldehyde and ethylcyanoacetate to afford 1,6-naphthyridine (**10b**). Antimicrobial screening of some of the synthesized compounds has been performed.

Keywords: 2,2,6,6-Tetramethyl-4-piperidone, triacetonamine, *N*-hydroxy-triacetonamine, formaldehyde.

Introduction

Preparation of 2,2,6,6-tetramethyl-piperidin-4-one (triacetonamine) still attract researchers all over the world because of its importance and various applications[1-3]. 2,2,6,6-Tetramethyl-piperidine derivatives have different biological effects. 2,2,6,6-Tetramethyl-piperidine derivatives have anticancer, analgesic, antipyretic and anticholinergic effects[4,5]. Also, 2,2,6,6-tetramethyl-piperidin-4-one have hypotensive and vasodilator activity as demonstrated by intravital microcirculation method[6].

3,5-Bis(4-(dimethylamino)benzylidene)-2,2,6,6-tetramethylpiperidin-4-one (**I**), and 8-(4chlorobenzylidene)-4-(4-chlorophenyl)-5,5,7,7-tetramethyl-3,4,5,6,7,8-hexahydropyrido[4,3-*d*]pyrimidine-2(1*H*)-thione (**II**) have more anticancer activity against breast cancer cell lines than reference drug used in the study (Fig. 1) [22]. 7-(4-Chlorobenzylidene)-3-(4-chlorophenyl)-4,4,6,6-tetramethyl-3,3a,4,5,6,7-hexahydro-2*H*-pyrazolo[4,3-*c*]

pyridine-2-carbothioamide (**III**) and *N*-(7-(2-Chlorobenzylidene)-3-(2-chlorophenyl)-4,4,6,6-tetramethyl-3,3a,4,5,6,7-hexahydro-2*H*-pyrazolo[4,3-*c*]pyridine-2-carbonothioyl)acetamide (**IV**) show high antitumor activity against hepatocellular carcinoma HepG2 cell lines[7].

1-Hydroxy-2,2,6,6-tetramethylpiperidin-4-one derivatives are used as antioxidants[8-10], contrast agents [11,12], spin probes [13-15], spin labels [16,17], hindered amine light stabilizers[18], nitroxide mediated radical polymerization agents[19,20].

Preparation of 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-one (*N*-hydroxy-triacetonamine) starting from 2,2,6,6-tetramethylpiperidin-4-one was done through two steps (Scheme 1)[21]. The methods of preparation of 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-one (*N*-hydroxy-triacetonamine) which is mentioned in the literature are difficult and expensive, so we will report simple and one step method for its

*Corresponding author e-mail: mahmoud_nabil18@yahoo.com, Tel. 00201225761858

Received 9/1/2019; Accepted 4/3/2019

DOI: 10.21608/ejchem.2019.7103.1586

© 2019 National Information and Documentation Center (NIDOC)

preparation (Scheme 1)[21].

Also, reactions of *N*-hydroxytriacetoneamine with various organic reagents will be reported.

Results and Discussion

2,2,6,6-Tetramethyl-4-piperidone contains different functions groups which could be used to react with various organic reagents. Active methylene adjacent to carbonyl group was used to prepare different chalcones which further react with different organic reagents[22]. In this article, we will prepare *N*-hydroxy derivative of triacetoneamine which will be the starting material. Although the oxygen of hydroxyl group linked to nitrogen in *N*-hydroxy-2,2,6,6-tetramethyl-4-piperidone (**2**) which is good electronegative atom, the oxygen atom of hydroxyl group is

still a nucleophile which can react with different electrophiles.

2,2,6,6-Tetramethyl-4-piperidone (**1**) reacts with hydrogen peroxide in potassium hydroxide to afford *N*-hydroxy-2,2,6,6-tetramethyl-4-piperidone (**2**) (Scheme 1). *N*-Hydroxy-2,2,6,6-tetramethyl-4-piperidone (**2**) reacts with formaldehyde to give compound (**3**) which reacts with piperidine to afford compound (**4**) (Scheme 2). Compound (**4**) can be prepared directly by reacting *N*-hydroxy-2,2,6,6-tetramethyl-4-piperidone (**2**) with formaldehyde and piperidine (Scheme 2). Spectral data (IR, MS, ¹H NMR) are in agreement with the assigned structure of compounds (**2**), (**3**) and (**4**). The mass spectrum of compound (**2**) shows molecular ion peak at *m/z* 171. The ¹H NMR spectrum of compound (**3**) show characteristic signal at δ 4.8 corresponding to OCH₂O. The IR spectrum of compound (**4**)






Fig. 1.



Scheme 1



Scheme 2

shows disappearance of absorption band for hydroxyl group.

N-Hydroxy-2,2,6,6-tetramethyl-4-piperidone (**2**) reacts with sodium azide to afford 1-azido-2,2,6,6-tetramethylpiperidin-4-one (**5**) and 1-azido-2,2,7-trimethyl-1,4-diazepan-5-one (**6**). Although separation of compound (**6**) was done accidentally, but it is expected. Ring expansion of piperidine derivative while reaction with sodium azide is reported[23]. The Infrared spectrum of compounds (**5**) and (**6**) show characteristic absorption band for azide group. Also, the IR spectrum of compound (**6**) show absorption band

for carbonyl group of amide. The ¹H NMR of compound (**6**) shows signal for CH₂N at δ 4.00.

N-Hydroxy-2,2,6,6-tetramethyl-4-piperidone (**2**) reacts with α-bromoacetoglucose and α-bromoacetoxylucose to afford 2-(acetoxymethyl)-6-((2,2,6,6-tetramethyl-4-oxopiperidin-1-yl)oxy)tetrahydro-2*H*-pyran-3,4,5-triyl triacetate (**7a**) and 2-((2,2,6,6-tetramethyl-4-oxopiperidin-1-yl)oxy)tetrahydro-2*H*-pyran-3,4,5-triyl triacetate (**7b**) respectively. Deacetylation of compounds (**7a,b**) were accomplished by ammonia solution to afford 2,2,6,6-tetramethyl-1-((3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2*H*-pyran-2-yl)oxy)

piperidin-4-one (**8a**) and 2,2,6,6-tetramethyl-1-((3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy) piperidin-4-one (**8b**). The structures of compounds (**7a,b**) and (**8a,b**) were elucidated from ¹H NMR, IR, and mass spectral data. The IR of compounds (**7a,b**) show disappearance of absorption band for hydroxyl group and appearance of absorption band for carbonyl group of an ester. The ¹H NMR of compound (**7a**) shows signal at δ2.30 corresponding to CH₃CO. The IR spectra of compounds (**8a,b**) show appearance of absorption band for hydroxyl group which indicate deacetylation of compounds (**7a,b**). *N*-Hydroxy-2,2,6,6-tetramethyl-4-piperidone (**2**) reacts with 2-(4-chlorobenzylidene)malononitrile to give 2-amino-4-(4-chlorophenyl)-3-cyano-5,5,7,7-tetramethyl-7,8-dihydro-1,6-naphthyridin-6(5*H*)-yl acetate (**9**). Also, *N*-hydroxy-2,2,6,6-tetramethyl-4-piperidone (**2**) reacts with *p*-chlorobenzaldehyde and cyanoacetamide to afford 2-amino-3-carbamoyl-8-(4-chlorobenzylidene)-4-(4-chlorophenyl)-5,5,7,7-tetramethyl-7,8-dihydro-1,6-naphthyridin-6(5*H*)-yl acetate (**10a**). In addition, *N*-hydroxy-2,2,6,6-tetramethyl-4-piperidone (**2**) reacts with *p*-chlorobenzaldehyde and ethylcyanoacetate to produce ethyl-6-acetoxy-2-amino-8-(4-

chlorobenzylidene)-4-(4-chlorophenyl)-5,5,7,7-tetramethyl-5,6,7,8-tetrahydro-1,6-naphthyridine-3-carboxylate (**10b**). The spectral data of compounds (**9**), and (**10a,b**) are compatible with the proposed structure. The IR spectrum of compound (**9**) shows absorption band for cyano group at 2201 cm⁻¹. The ¹H NMR spectrum of compound (**9**) shows signal for aromatic protons at 7.25 and 7.68. The ¹³C NMR of compound (**9**) shows signals for SP² carbon. The IR spectrum of compound (**10a**) show absorption band for carbonyl group of amide at 1644 cm⁻¹. The ¹H NMR of compounds (**10a,b**) show signals at δ 4.73 and 5.99 corresponding to hydrogen linked to SP² carbon.

Antimicrobial activity

The antimicrobial activity of new compounds was done according to reported procedure[24]. Antimicrobial screening of some of the synthesized compounds is summarized in the following table (Table 1). Most of tested compounds show moderate activity against reference drug. Compound (**5**) shows highest antibacterial activity against reference drug cefotaxime. Also, compound (**10a**) shows highest antifungal activity against reference drug nystatin.

TABLE 1. Antimicrobial activities of some prepared compounds (diameter of inhibition zones in mm.).

Compound No.	Gram positive bacteria		Gram negative bacteria		Fungi
	<i>B. subtilis</i>	<i>B. cereus</i>	<i>P. aeruginosa</i>	<i>E. coli</i>	<i>Aspergillusniger</i>
2	10	20	20	18	10
3	12	25	12	13	14
4	14	21	15	14	19
5	50	10	16	11	15
9	10	4	14	15	20
10a	16	9	21	10	26
Cefotaxime	26	28	30	29	-
Nystatin	-	-	-	-	20

Experimental

All melting points are uncorrected and measured using Electro-thermal IA 9100 apparatus (Shimadzu, Tokyo, Japan). IR spectra were recorded as potassium bromide pellets on a Perkin-Elmer 1650 spectrophotometer (Perkin-Elmer, Norwalk, CT, USA). ¹H NMR was determined on a Jeol-Ex-400 NMR spectrometer (Jeol, Tokyo, Japan) and chemical shifts were expressed as part per million; ppm (δ values) against TMS as internal standard. Mass spectra were recorded on VG 2AM-3F mass spectrometer (Thermo electron corporation, USA). Microanalyses were operated

using Mario El Mentar apparatus and satisfactory results were within the accepted range (±0.30) of the calculated values. Follow up the reactions and checking the purity of the compounds was made by TLC on silica gel-protected aluminium sheets (Type 60 F254, Merck). Mass spectra, and elemental analysis were done in Microanalytical Centre in Faculty of Science, Cairo University. ¹H & ¹³C NMR, IR spectra, and antimicrobial activity were done in National Research Centre, Cairo, Egypt. All used chemicals were of reagent grade and were used as supplied directly unless otherwise stated.

1-Hydroxy-2,2,6,6-tetramethylpiperidin-4-one (2)

Triacetoneamine **1** (1.55 g, 0.01 mol.) was dissolved in 20 ml methanol. This solution was added to 20 ml acetone containing KOH solution (1g. KOH in 5 ml H₂O). Then, we add 5 ml H₂O₂ (36 %) dropwise with stirring at room temperature. The reaction mixture is heated at 70 °C with stirring for 2 hours. The reaction mixture is evaporated under reduced pressure. The solid residue crystallized from water to give compound **2** in 71 % yield (m.p. 88-90 °C). IR (KBr, cm⁻¹) v: 3490 (OH), 1709 (C=O). MS, m/z (%) 171 (M+, 90%), 140 (M+-OH, 34%). ¹H NMR (CDCl₃) δ ppm: 1.15 (s, 6H, 2CH₃), 1.17 (s, 6H, 2 CH₃), 2.17 (s, 4H, 2 CH₂), 7.25 (brs, 1H, OH). Anal. calcd. For C₉H₁₇NO₂ (171.24): C, 63.13; H, 10.01; N, 8.18. Found: C, 63.09; H, 9.94; N, 8.03.

1 - (H y d r o x y m e t h o x y) - 2 , 2 , 6 , 6 - tetramethylpiperidin-4-one (3)

A mixture of compound **2** (0.01 mole), and formaldehyde (0.01 mole) is heated under reflux with stirring in 50 ml absolute ethanol for 1 hour. The reaction mixture is evaporated under reduced pressure to give solid residue. The solid is recrystallized from ethanol to afford compound **3** (yield 62 %, m.p. 105-107 °C). IR (KBr, cm⁻¹) v: 3440 (OH), 1714 (C=O). MS, m/z (%) 201 (M+, 90%), 184 (M+-OH, 34%). ¹H NMR (CDCl₃) δ ppm: 1.13 (s, 6H, 2 CH₃), 1.17 (s, 6H, 2 CH₃), 2.20 (s, 4H, 2 CH₂), 4.8 (s, 2H, CH₂), 6.15 (brs, 1H, OH). Anal. calcd. For C₁₀H₁₉NO₃ (201.27): C, 59.68; H, 9.52; N, 6.96. Found: C, 59.59; H, 9.48; N, 6.88.

*2,2,6,6-Tetramethyl-1-(piperidin-1-ylmethoxy) piperidin-4-one (4)**Method A*

A mixture of compound **3** (0.01 mole), piperidine (0.01 mole) is refluxed in 50 mL absolute ethanol under TLC control. The reaction mixture is evaporated under reduced pressure. The residue collected crystallized from ethanol to give compound **4** (yield 61 %). IR (KBr, cm⁻¹) v: 1709 (C=O). MS, m/z (%) 268 (M+, 46%). ¹H NMR (CDCl₃) δ ppm: 1.13 (s, 6H, 2 CH₃), 1.17 (s, 6H, 2 CH₃), 1.45 (m, 6H, 3CH₂), 1.80 (s, 4H, 2 CH₂), 2.43 (t, 4H, J=7.1 Hz, CH₂N), 5.30 (s, 2H, OCH₂N). Anal. calcd. For C₁₅H₂₈N₂O₂ (268.40): C, 67.13; H, 10.52; N, 10.44. Found: C, 67.21; H, 10.60; N, 10.52.

Method B

A mixture of compound **2** (0.01 mole), and formaldehyde (0.01 mole), piperidine (0.01 mole) are heated under reflux with stirring in 50 ml absolute ethanol under TLC control. The reaction

mixture is evaporated under reduced pressure to give solid residue. The solid is recrystallized from ethanol to afford compound **4** (yield 69 %, m.p. 95-97 °C).

Preparation of compounds(5) and (6)

Compound **2** (0.01 mole) is refluxed with sodium azide (0.01 mole) in 5 mL acetic acid and 4 drops of water for 15 minutes. The precipitate formed is filtered, dried and crystallized from benzene to afford compound **5**. The filtrate is evaporated under reduced pressure to produce compound **6**.

1-Azido-2,2,6,6-tetramethylpiperidin-4-one (5)

Yield 73%, m.p. 220-222 °C, brown powder. IR (KBr, cm⁻¹) v: 2125 (N₃), 1722 (C=O). MS, m/z (%) 196 (M+, 36%). ¹H NMR (CDCl₃) δ ppm: 1.36 (s, 6H, 2 CH₃), 1.57 (s, 6H, 2 CH₃), 1.92 (s, 4H, 2 CH₂). ¹³C NMR (CDCl₃) δ ppm: 29.3 (4CH₃), 53.5 (2C), 54.1 (2CH₂), 173.9 (C=O). Anal. calcd. For C₉H₁₆N₄O (196.25): C, 55.08; H, 8.22; N, 28.55. Found: C, 55.12; H, 8.28; N, 28.60.

1-Azido-2,2,7-trimethyl-1,4-diazepan-5-one(6)

Yield 10 %, m.p.190-192 °C, brown powder. IR (KBr, cm⁻¹) v: 3300 (NH), 2130 (N₃), 1693 (C=O). MS, m/z (%) 211 (M+, 70%). ¹H NMR (CDCl₃) δ ppm: 1.16 (s, 6H, 2 CH₃), 1.41 (s, 6H, 2 CH₃), 2.14 (s, 2H, CH₂), 4.00 (s, 2H, CH₂N), 5.01 (brs, 1H, NH). ¹³C NMR (CDCl₃) δ ppm: 22.1, 25.0, 28.6, 32.8 (4CH₃), 47.0, 53.5 (2C), 56.3, 57.7 (CH₂), 173.9 (C=O). Anal. calcd. For C₉H₁₇N₅O (211.27): C, 51.17; H, 8.11; N, 33.15. Found: C, 51.20; H, 8.18; N, 33.20.

General method for preparation of compounds(7a,b)

2,3,4,6-Tetra-O-acetyl-α-D-glucopyranosyl bromide or 2-hydroxytetrahydro-2H-pyran-3,4,5-triyl triacetate (0.005 mole) dissolved in acetone (15 mL) was added portion-wise to a clear solution of compound **2** (0.005 mole) and potassium hydroxide (0.28g, 0.005 mole) in distilled water (2 ml). The reaction mixture was stirred at room temperature until reaction was judged complete by TLC(pet. ether/ethyl acetate, 4:1 v/v). Evaporation of the solvent afforded a residue which was washed with distilled water (10 mL) followed by extraction with chloroform. The obtained residue after removal of chloroform was triturated with petroleum ether (b.p. 40-60 °C) (45 mL) with stirring. The solid product was filtered, dried and recrystallized from ethanol to produce compound **7a,b**.

2-(Acetoxymethyl)-6-((2,2,6,6-tetramethyl-4-oxopiperidin-1-yl)oxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate(7a)

IR (KBr, cm^{-1}) ν : 1709 (C=O), 1742 (C=O). MS, m/z (%) 501 (M⁺, 31%). ¹H NMR (CDCl_3) δ ppm: 1.23 (s, 6H, 2 CH₃), 1.47 (s, 6H, 2 CH₃), 2.21 (s, 4H, 2CH₂), 2.30 (s, 12H, 4 CH₃), 4.73 (t, 3H, $J=7$ Hz, CHO), 5.30 (d, 2H, $J=7$ Hz, CH₂), 5.80 (d, 2H, $J=7$ Hz, CH₂). Anal.calcd. For C₂₃H₃₅NO₁₁ (501.35): C, 55.08; H, 7.03; N, 2.79. Found: C, 55.11; H, 7.09; N, 2.82.

2-((2,2,6,6-tetramethyl-4-oxopiperidin-1-yl)oxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate(7b)

IR (KBr, cm^{-1}) ν : 1721 (C=O), 1737 (C=O). MS, m/z (%) 429 (M⁺, 12%). ¹H NMR (CDCl_3) δ ppm: 1.23 (s, 6H, 2 CH₃), 1.29 (s, 6H, 2 CH₃), 2.10 (s, 4H, 2CH₂), 2.20 (s, 9H, 3 CH₃), 3.83 (t, 2H, $J=7$ Hz, CHO), 5.34 (q, 1H, $J=7$ Hz, CH), 5.54 (d, 2H, $J=7$ Hz, CH₂), 5.74 (d, 2H, $J=7$ Hz, CH). Anal.calcd. For C₂₀H₃₁NO₉ (429.47): C, 55.93; H, 7.28; N, 3.26. Found: C, 56.01; H, 7.32; N, 3.31.

General method for preparation of compounds (8a,b)

The acetylated glycosides **7a,b** (5 mmol) was dissolved in dry saturated methanolic ammonia solution (20 mL) and stirred at 0 °C for 1 h, then stirring was persisted at r.t. for 5 h. Removal of the solvent under vacuum at 40 °C gave a solid residue, which was recrystallized from ethanol to give the corresponding free glycoside 8a,b.

2,2,6,6-tetramethyl-1-((3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)piperidin-4-one(8a)

IR (KBr, cm^{-1}) ν : 3350 (OH), 1739 (C=O). MS, m/z (%) 333 (M⁺, 16%). ¹H NMR (CDCl_3) δ ppm: 1.35 (s, 6H, 2 CH₃), 1.61 (s, 6H, 2 CH₃), 2.35 (s, 4H, 2CH₂), 3.61 (t, 3H, $J=7$ Hz, 3 CH), 3.71 (q, 1H, $J=7$ Hz, CH), 3.80 (d, 2H, $J=7$ Hz, CH₂), 4.80 (d, 2H, $J=7$ Hz, OCH₂O), 6.21 (brs, 4H, OH). Anal.calcd. For C₁₅H₂₇NO₇ (333.38): C, 54.04; H, 8.16; N, 4.20. Found: C, 54.10; H, 8.19; N, 4.29.

2,2,6,6-tetramethyl-1-((3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)piperidin-4-one(8b)

IR (KBr, cm^{-1}) ν : 3410 (OH), 1742 (C=O). MS, m/z (%) 303 (M⁺, 12%). ¹H NMR (CDCl_3) δ ppm: 1.41 (s, 6H, 2 CH₃), 1.52 (s, 6H, 2 CH₃), 2.25 (s, 4H, 2CH₂), 3.70 (t, 2H, $J=7$ Hz, 2 CH), 3.78 (q, 1H, $J=7$ Hz, CH), 3.91 (d, 2H, $J=7$ Hz, CH₂), 5.21 (d, 1H, $J=7$ Hz, OCHO), 7.1 (brs, 3H, 3OH). Anal.calcd. For C₁₄H₂₅NO₆ (303.36): C, 55.43; H, 8.31; N, 4.62. Found: C, 55.49; H, 8.37; N, 4.68.

2-Amino-4-(4-chlorophenyl)-3-cyano-5,5,7,7-tetramethyl-7,8-dihydro-1,6-naphthyridin-6(5H)-yl acetate(9)

Compound **2** (0.01 mole) is heated under reflux for 4 hours with 2-(4-chlorobenzylidene) malononitrile (0.01 mole) in ammoniumacetate (1 g.) and acetic acid (10 mL). The reaction mixture is poured into water. The solid precipitate is filtered, dried, crystalized from ethanol/ water mixture (5:1). Yield 71 %, m.p. 180-182°C, brown powder. IR (KBr, cm^{-1}) ν : 3364 (NH₂), 2201 (CN), 1759 (C=O). MS, m/z (%) 398 (M⁺, 23%). ¹H NMR (CDCl_3) δ ppm: 1.24 (s, 6H, 2 CH₃), 1.35 (s, 6H, 2 CH₃), 2.03 (s, 2H, CH₂), 2.44 (s, 3H, CH₃), 5.41 (brs, 2H, NH₂), 7.25 (d, 2H, $J=7.5$ Hz, Ar), 7.68 (d, 2H, $J=7.5$ Hz, Ar). ¹³C NMR (CDCl_3) δ ppm: 1.0, 1.7, 24.8, 29.7, 30.9, 113.7 (CN), 128.6, 128.9, 129.0, 129.1, 129.1, 129.2, 129.4, 135.0, 136.0 (Ar-C), 153.8 (C=O). Anal.calcd. For C₂₁H₂₃ClN₄O₂ (398.89): C, 63.23; H, 5.81; N, 14.05. Found: C, 63.30; H, 5.88; N, 14.09.

2-Amino-3-carbamoyl-8-(4-chlorobenzylidene)-4-(4-chlorophenyl)-5,5,7,7-tetramethyl-7,8-dihydro-1,6-naphthyridin-6(5H)-yl acetate(10a)

Compound **2** (0.01 mole) is heated under reflux for 4 hours with *p*-chlorobenzaldehyde (0.02 mole) and cyanoacetamide (0.01 mole) in ammonium acetate (1 g.) and acetic acid (10 mL). The reaction mixture is poured into water. The precipitate formed is filtered, dried, crystalized from ethanol. Yield 63 %, m.p. 235-237°C, dark brown powder. IR (KBr, cm^{-1}) ν : 3425 (NH₂), 1644 (C=O). MS, m/z (%) 539 (M⁺, 10%). ¹H NMR (CDCl_3) δ ppm: 1.18 (s, 6H, 2 CH₃), 1.71 (s, 6H, 2 CH₃), 2.46 (s, 3H, CH₃), 4.73 (s, 1H, =CH), 6.79 (d, 4H, $J=7.5$ Hz, Ar), 7.55 (d, 4H, $J=7.5$ Hz, Ar), 7.79 (brs, 2H, NH₂), 12.72 (brs, 2H, NH₂). ¹³C NMR (CDCl_3) δ ppm: 10.3 (4CH₃), 20.3, 40.2, 45.5 (C), 116.4 (CH=), 116.4, 120.6, 128.3, 128.7, 128.9, 129.1, 129.2, 129.8 (Ar), 165.3, 161.9 (2 C=O). Anal.calcd. For C₂₈H₂₈Cl₂N₄O₃ (539.46): C, 62.34; H, 5.23; N, 10.39. Found: C, 62.39; H, 5.28; N, 10.42.

Ethyl-6-acetoxy-2-amino-8-(4-chlorobenzylidene)-4-(4-chlorophenyl)-5,5,7,7-tetramethyl-5,6,7,8-tetrahydro-1,6-naphthyridine-3-carboxylate (10b)

Compound **2** (0.01 mole) is heated under reflux for 4 hours with *p*-chlorobenzaldehyde (0.02 mole) and ethylcyanoacetate (0.01 mole) in ammonium acetate (1 g.) and acetic acid (10 mL). The reaction mixture is poured into water. The

precipitate formed is filtered, dried, crystalized from ethanol/water (5:1). Yield 51 %, m.p. 210-212°C, pale yellow powder. IR (KBr, cm⁻¹) v: 3452 (NH₂), 1737 (C=O). MS, m/z (%) 568 (M⁺, 7%). ¹H NMR (CDCl₃) δ ppm: 1.20 (s, 6H, 2 CH₃), 1.69 (s, 6H, 2 CH₃), 1.75 (t, 3H, J=8 Hz, CH₃), 2.04 (s, 3H, CH₃), 3.78 (q, 2H, J=8 Hz, OCH₂), 5.99 (s, 1H, =CH), 7.25 (d, 4H, J=7.5 Hz, Ar), 7.37 (d, 4H, J=7.5 Hz, Ar), 7.48 (brs, 2H, NH₂). ¹³C NMR (CDCl₃) δ ppm: 13.4, 13.5, 45.3, 50.2, 50.8, 57.8, 58.7, 61.5, 62.6, 99.8, 128.1, 128.9, 129.01, 129.04, 129.1, 129.2, 129.6, 129.7 (Ar-C), 166.0, 166.3 (2 C=O). Anal. calcd. For C₃₀H₃₁Cl₂N₃O₄ (568.50): C, 63.38; H, 5.50; N, 7.39. Found: C, 63.42; H, 5.56; N, 7.42.

References

- Zhou Z., Zhang Q., Meng H., Zhang X., Liu G., Zhang X., Eco-friendly production method of tetramethylpiperidone. Patent No. CN 107602447 (2018).
- Zhao X., Liu J., Zhao H., Ma G., Process and device for the production of triacetoneamine. Patent no. CN 107033066 (2017).
- Chen L., Deng Z., Su B., Li X., Wu P., Cai C., Li Y., Method for continuously synthesizing triacetoneamine with low temperature liquid phase reaction fixed bed. Patent no. CN 106866503 (2017).
- Navajas C., Atarah R., Gynther J., Theoretical study of possible cholinergic substances by means of quantum and molecular mechanics calculations. *THEOCHEM*, **362** (1), 133-140 (1996) doi: 10.1016/0166-1280(95)04368-3.
- Dagonneau M., Kagan E. S., Mikhailov V. I., Rozantsev E. G., Sholle V. D., Chemistry of Hindered Amines from the Piperidine Series. *Synthesis*, **11**, 895-916 (1984) doi: 10.1055/s-1984-31014.
- Anthony K., Xu S., Lin Y., Long K., Hypotensive and vasodilator effects of triacetoneamine as demonstrated by intravital microcirculation method. *Acta Pharmacologia Sinica*, **8** (1), 49-53 (1987).
- Mahmoud N. M. Yousif, Ahmed A. Fayed, Nabil M. Yousif, Reactions of Triacetoneamine Part II, Synthesis of Novel Pyrazolo(4,3-c)pyridine Derivatives, and 2-(Piperidin-4-ylidene)hydrazinecarbothioamide Derivatives Derived From 2,2,6,6-Tetramethyl-piperidin-4-one for In vitro Anticancer Evaluation. *Der Pharma Chemica*, **10** (8), 105-109 (2018).
- Krishna M. C., Russo A., Mitchell J. B., Goldstein S., Dani H., Samuni A., Do Nitroxide Antioxidants Act as Scavengers of O₂ or as SOD Mimics? *J. Biol. Chem.*, **271**, 26026-26031 (1996) doi: 10.1074/jbc.271.42.26026.
- Xavier S., Yamada, K., Samuni A. M., Samuni A., De Graff W., Krishna M. C., Mitchell J. B., Differential protection by nitroxides and hydroxylamines to radiation-induced and metal ion-catalyzed oxidative damage. *Biochim Biophys. Acta*, **1573**, 109-120 (2002) doi: 10.1016/S0304-4165(02)00339-2.
- Miura Y., Utsumi H., Hamada A., Antioxidant activity of nitroxide radicals in lipid peroxidation of rat liver microsomes. *Arch Biochem. Biophys.*, **300** (1), 148-156 (1993) doi: 10.1006/abbi.1993.1021.
- Matsumoto K., Hyodo F., Matsumoto A., Koretsky A. P., Sowers A. L., Mitchell J. B., Krishna M. C., High-Resolution Mapping of Tumor Redox Status by Magnetic Resonance Imaging Using Nitroxides as Redox-Sensitive Contrast Agents. *Clin Cancer Res.*, **12**, 24555-2462 (2006) doi: 10.1158/1078-0432.CCR-05-2747.
- Hyodo F., Chuang K. H., Goloshevsky A. G., Sulimma A., Griffiths G. L., Mitchell J. B., Koretsky A. P., Krishna M. C., Brain Redox Imaging Using Blood Brain Barrier Permeable Nitroxide MRI Contrast Agent. *J. Cereb. Blood Flow Metab.*, **28**, 1165-1174, (2008) doi: 10.1038/jcbfm.2008.5.
- Yamada K., Yamamiya I., Utsumi H., In vivo detection of free radicals induced by diethylnitrosamine in rat liver tissue. *Free Radical Biol. Med.*, **40**, 2040-2046 (2006) doi: 10.1016/j.freeradbiomed.2006.01.031.
- Yordanov A. T., Yamada Ki. K., Krishna M. C., Mitchell J. B., Woller E., Cloninger M., Brechbiel M. W., Spin-Labeled Dendrimers in EPR Imaging with Low Molecular Weight Nitroxides. *Angew. Chem. Int. Ed.*, **40**, 2690-2692 (2001).
- Utsumi H., Yamada K., Ichikawa K., Sakai K., Kinoshita Y., Matsumoto S., Nagai M., Simultaneous molecular imaging of redox reactions monitored by Overhauser-enhanced MRI with ¹⁴N- and ¹⁵N-labeled nitroxyl radicals. *Proc. Nat. Acad. Sci. U.S.A.*, **103**, 1463-1468, (2006) doi: 10.1073/pnas.0510670103.
- Borbat P. P., Costa-Filho A. J., Earle K. A., Moscicki J. K., Freed J. H., Electron Spin Resonance in Studies of Membranes and Proteins. *Science*, **291**, 266-269 (2001) doi:10.1126/science.291.5502.266.

17. Barhate N., Cekan P., Massey A. P., Sigurdsson S. T., A Nucleoside That Contains a Rigid Nitroxide Spin Label: A Fluorophore in Disguise. *Angew. Chem., Int. Ed.*, **46**, 2655-2658 (2007) doi:10.1002/anie.200603993.
18. Carlsson J., Chan K. H., Durmis J., Wiles D. M., Decomposition of polypropylene hydroperoxide by hindered amines. *J. Polym. Sci., Polym. Chem. Ed.*, **20**, 575-582 (1982) doi:10.1002/pol.1982.170200231.
19. Miura Y., Nakamura N., Taniguchi I., Low-Temperature "Living" Radical Polymerization of Styrene in the Presence of Nitroxides with Spiro Structure. *Macromolecules*, **34**, 447-455 (2001) doi: 10.1021/ma0012752.
20. Wetter C., Gierlich J., Knoop C. A., Muller C., Schulte T., Studer A., Steric and Electronic Effects in Cyclic Alkoxyamines—Synthesis and Applications as Regulators for Controlled/Living Radical Polymerization. *Chem. Eur. J.*, **10**, 1156-1166 (2004) doi:10.1002/chem.200305427.
21. Paleos C. M., Ready reduction of some nitroxide free radicals with ascorbic acid. *J. C. S. Chem. Comm.*, 345-346 (1977) doi:10.1039/C39770000345.
22. Soliman H. A., Yousif M. N. M., Said M. M., Hassan N. A., Ali M. M., Awad H. M. and Abdel-Megeid F. M. E., Synthesis of novel 1,6-naphthyridines, pyrano [3,2-c] pyridines and pyrido [4,3-d] pyrimidines derived from 2,2,6,6-tetramethylpiperidin-4-one for in vitro anticancer and antioxidant evaluation, *Der Pharma Chemica*, **6** (3), 394-410 (2014).
23. Dickerman S. C., Lindwall H. G., Studies in piperidone chemistry. I. A. synthesis of 5-homopiperazinones. *J. Org. Chem.*, **14** (4), 530-536 (1949) doi: 10.1021/jo01156a005.
24. Reeves D.S., Hite L.O., *Principles Methods of Assaying Antibiotic in Pharmaceutical Microbiology*, 3rd Edi., Blackwell Scientific, Oxford, 140 (1983).

تحضير، التفاعلات، و الفاعليه ضد الميكروبات لمشتقات ان-هيدروكسي-تراياسيتونامين

محمود نبيل محمود يوسف¹، احمد عبد الحميد فايد²، نبيل محمود يوسف¹

¹قسم الكيمياء الضوئية - المركز القومي للبحوث - القاهرة - مصر.

²قسم العلاج الصدري - كلية علوم التأهيل الطبي - جامعة طيبة - المدينة المنوره - 22624، المملكة العربية السعودية.

تم تحضير ان-هيدروكسي-تراياسيتونامين 1 في خطوه واحده و بسيطه. ان-هيدروكسي-تراياسيتونامين 1 يتفاعل مع العديد من الكواشف العضويه. ان-هيدروكسي-تراياسيتونامين 1 يتفاعل مع الفورمالدهايد و الفورمالدهايد و البيبريدين لتحضير مركبات 3 و 4. ان-هيدروكسي-تراياسيتونامين 1 يتفاعل مع ازيد الصوديوم و الفا بروموشوجر لكي يكون المركبات المقابله. ان-هيدروكسي-تراياسيتونامين 1 يتفاعل مع مشتق من المالنونيتريل لكي يكون مشتق من 1,6-نفثريدين 9. ان-هيدروكسي-تراياسيتونامين 1 يتفاعل ايضا مع بارا كلوروبنز الدهايد و سيانواسيتاميد لكي يكون مشتق من 1,6 نفثريدين 10a. ان-هيدروكسي-تراياسيتونامين 1 يتفاعل ايضا مع بارا كلوروبنز الدهايد و ايثيل سيانو اسيتات لكي يكون مشتق من 1,6 نفثريدين 10b. الفاعليه ضد الميكروبات لبعض المركبات المحضره تم قياسها.